Understanding how GSTP1 affects breast cancer and its treatment
Official title: Investigating GSTP1 as a novel regulator of the cysteine redoxome in breast cancer and maker of vulnerability to redox-based therapy
Funded at Washington University · NIH-10753588 · Data updated 2026-11-12
This study is looking at how a specific enzyme called GSTP1 affects breast cancer cells and their response to treatment, with the hope of finding new ways to make treatments more effective for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | December 12, 2022 |
| Project end | November 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $207,185 |
| NIH project number | 5R21CA270876-02 |
| Project ID | NIH-10753588 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with breast cancer, particularly those with luminal or Her2 positive subtypes.
✕Less likely to help
Patients with breast cancer types that do not involve GSTP1 silencing may not benefit from this research.
What this research studies
This research investigates the role of the enzyme GSTP1 in breast cancer, particularly how its silencing affects cancer cell behavior and treatment responses. By examining cancer cell lines and patient tumors, the study aims to uncover how reduced GSTP1 expression can create vulnerabilities in breast cancer cells, potentially leading to new therapeutic strategies. The researchers will explore the molecular changes that occur when GSTP1 is silenced, focusing on how this impacts redox signaling and cancer transformation. Patients may benefit from insights that could lead to more effective treatments targeting GSTP1-related pathways.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for breast cancer patients by identifying vulnerabilities in cancer cells.
How similar studies have gone: Previous research has shown promising results in targeting metabolic vulnerabilities in cancer, suggesting that this approach may yield significant insights.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Held, Jason M. — Washington University
- Study coordinator: Held, Jason M.
Related research
Other NIH-funded projects on the same topics.
-
Improving Breast Cancer Guideline Adherence in Nigeria
Aimed at helping doctors in Nigeria follow international guideline-based breast cancer care to improve outcomes for women with breast cancer.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Translational breast cancer research to improve treatment options
A comprehensive program at Baylor College of Medicine is focusing on breast cancer; researchers will advance targeted therapies and biomarkers to help patients with aggressive or hard-to-treat forms.
-
Cancer Pain Management for Asian American Breast Cancer Survivors with Depressive Symptoms
A technology-based program helps Asian American breast cancer survivors with depressive symptoms manage chronic pain more effectively from home using a web app and mobile tools.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Gut bacteria and metabolites linked to breast density and cancer risk
A small, patient-friendly study will explore whether gut bacteria and their byproducts are connected to high breast density, which can raise cancer risk and make screening less accurate.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.